Sensius key facts
as of Oct 2026- Developer of a thermotherapy system designed to improve treatment outcomes for head and neck cancer patients.
- Sensius is valued at approximately $44.0M as of Oct 2026 (last reported valuation).
- It has raised $21.5M; the latest was Later Stage VC ($16.9M) in May 2025.
- Notable investors include European Innovation Council, European Commission, UCEA Capital Partners, Coöperatieve Rabobank., Coöperatieve Rabobank — 14 tracked in total.
- Status: Privately Held (backing).
Sensius's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·The complete investor list: 14 names
- ·Watch Sensius: the Monday email on marks, rounds and moves
Sensius funding rounds
No funding rounds for Sensius are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Sensius
14+Sensius valuation
Sensius's last reported valuation was $44 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
Sensius investors
14 investors are on record for Sensius, including European Innovation Council, European Commission, UCEA Capital Partners and Coöperatieve Rabobank..
About Sensius
Developer of a thermotherapy system designed to improve treatment outcomes for head and neck cancer patients. The company offers a hyperthermia system with integrated microwave sources and interactive software, enabling oncology clinics to enhance traditional therapies and reduce side effects for patients.
- Sector
- Healthcare
- HQ
- Rotterdam, Netherlands
- Founded
- 2015
- Employees
- 30
- Website
- sensiusthermotherapy.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.